SOBI:STO
Swedish Orphan Biovitrum
SEK 427,20
arrow_downward
-1,48%(-6,40) 1D
13 okt, 17:29:57 GMT+2 · SEK
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor SOBI genereren…
Openen
SEK 433,60
Hoog
SEK 437,40
Laag
SEK 420,40
Beursw.
152,78 mld.
Gem. vol.
269,95K
Volume
332,11K
Koers/winst-verhouding
114,10
52 wk hoog
SEK 487,00
52 wk laag
SEK 293,60
WPA
SEK 3,74
Uitstaande aandelen
357,64 mln.
Aantal medewerkers
2K
Openen
SEK 433,60
Hoog
SEK 437,40
Laag
SEK 420,40
Beursw.
152,78 mld.
Gem. vol.
269,95K
Volume
332,11K
Koers/winst-verhouding
114,10
52 wk hoog
SEK 487,00
52 wk laag
SEK 293,60
WPA
SEK 3,74
Uitstaande aandelen
357,64 mln.
Aantal medewerkers
2K
Nieuwsartikelen
Van webbronnen en nieuwspartners
Yahoo Finance
·
1 dag geleden
Earnings Preview: Swedish Orphan Biovitrum (BIOVF) Q3 Earnings Expected to Decline
Profiel
Sobi - Swedish Orphan Biovitrum AB is an international biopharmaceutical company focused on rare diseases. The company develops, commercializes, and delivers therapies in the fields of haematology, immunology and specialty care. Headquartered in Stockholm, Sweden, with major hubs in Basel, Switzerland, and Waltham, USA.
Sobi has a global presence in approximately 30 countries and provides medicines to patients in many more around world. The company develops treatments for patients living with complex and chronic rare conditions and maintains a pipeline of development and lifecycle management programs focused on advancing innovative therapies for diseases with significant unmet medical needs. Wikipedia
Over Swedish Orphan Biovitrum